Search results
This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases. Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology
Patients with ANCA-associated vasculitis who have undergone plasma exchange adjunctive therapy or usual care, maintenance therapy: cyclosporine versus maintenance therapy: cyclophosphamide Table S28.
Apr 8, 2021 · This article provides an in-depth, up-to-date summary of recent trials and suggests treatment algorithms for induction and maintenance of remission based on the latest guidelines. Future possible therapies in AAV will also be discussed.
- Karla N. Samman, Carolyn Ross, Christian Pagnoux, Jean-Paul Makhzoum
- 10.1155/2021/5534851
- 2021
- Int J Rheumatol. 2021; 2021: 5534851.
Evaluate benefits and harms of reduced starting doses of GC (eg, 0.5 mg/day) compared with standard starting doses (1 mg/kg/day) in patients with different ANCA subtypes, severity stages and risk factors for adverse outcomes. Investigate optimal duration of therapy with GC.
Jan 2, 2024 · We recommend biopsies and ANCA testing to assist in establishing a diagnosis of AAV. For remission induction in life-threatening or organ-threatening AAV, we recommend a combination of high-dose glucocorticoids (GCs) in combination with either rituximab or cyclophosphamide.
Treatment options include glucocorticoids, nonglucocorticoid immunosup-pressive agents, and surgical management of vascular abnormal-ities (12).
People also ask
How should patients with ANCA-associated vasculitis (AAV) be treated?
Does plasma exchange reduce circulating ANCA levels?
Can ANCA recur after kidney transplantation?
These guidelines present the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of: ANCA–associated vasculitides: Granulomatosis with polyangiitis (GPA), Microscopic polyangiitis (MPA), and Eosinophilic granulomatosis with polyangiitis (EGPA)
